# Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

> **NCT00240565** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 93 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Tositumomab 450 mg
- **DRUG:** Tositumomab 35 mg

## Key facts

- **NCT ID:** NCT00240565
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2007-02
- **Final completion:** 2011-09
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2012-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240565, "Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00240565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*